Previous studies have shown that a large proportion of pts with T2D are not at glycemic target, but the distance to target is not well characterized, including among high risk patients such as those with eCVD/CKD. The objective of the study was to assess the distance to glycemic target by eCVD/CKD status. This retrospective study using GE Centricity Electronic Medical Record database (2016 data) included adult T2D pts on metformin monotherapy with ≥12 months of enrollment prior to index date (initiation of metformin) and prescribed an add-on agent. Distance to target was calculated as median difference from 3 HbA1c targets: <7%, <7.5% and <8%. Of the 1741 included pts, mean age was 57 years, 49% were female, 25% had eCVD/CKD. Table shows the distance to glycemic targets by eCVD/CKD status. Median difference from target ranged from 0.2%-1.2% depending on the specified threshold. 44.6%, 33.6% and 25.6% of pts were ≥1.5% away from targets of 7%, 7.5% and 8%, respectively, at time of add-on therapy. Difference from target and proportion of pts ≥1.5% from target was even higher for those without compared to with eCVD/CKD.

In conclusion, a significant proportion of pts on metformin are more than 1.0% away from glycemic targets at the time of intensification and those without eCVD/CKD are likely to be intensified at much higher HbA1c.


G. Fernandes: None. B. Sawhney: Consultant; Self; Merck & Co., Inc. H. Hannachi: Employee; Self; Merck & Co., Inc. T. Wang: Employee; Spouse/Partner; Johnson & Johnson. Employee; Self; Merck & Co., Inc. A. McNeill: Employee; Self; Merck & Co., Inc. K. Iglay: Employee; Self; Merck & Co., Inc. Stock/Shareholder; Self; Merck & Co., Inc. S. Rajpathak: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at